Opus Genetics, INC Form 4 insider transactions

Amy Zaremba Rabourn, SVP of Finance at Opus Genetics, reported disposing of 8,190 shares of common stock on February 4, 2025, at a price of $1.14 per share.

Bernhard Hoffmann, SVP of Corporate Development at Opus Genetics, reported the disposal of 6,751 shares of common stock at a price of $1.14 on February 4, 2025.

Opus Genetics director James S.J. Manuso acquired 50,222 shares of common stock in lieu of cash compensation for board services.

Opus Genetics director, Jean Bennett, acquired 34,021 shares of common stock on January 2, 2025, as compensation for board services.

Opus Genetics CEO, George Magrath, recently acquired 100,000 shares of company stock at an average price of $0.976 per share.

Opus Genetics CEO, George Magrath, received 6,200 shares to correct an over-withholding error from a previous vesting of restricted stock units.

Opus Genetics President, Benjamin R. Yerxa, purchased 10,000 shares of common stock at $0.9834 per share on November 21, 2024.

Opus Genetics CEO, George Magrath, has increased his holdings in the company through multiple stock purchases in mid-November 2024.

Benjamin Yerxa, President of Opus Genetics, was granted 332,800 shares of common stock on November 7, 2024, as part of a restricted stock unit agreement.

CEO George Magrath reported disposing of 37,050 shares of Opus Genetics, Inc. common stock to cover tax obligations.

Adrienne L Graves, a director at Opus Genetics, acquired stock options for 172,874 shares on October 22, 2024.

Director Jean Bennett acquired 100,000 shares of common stock and stock options for 172,874 shares in Opus Genetics, Inc.

Director Richard J. Rodgers reports acquisition of 41,143 shares of common stock and disposal of 239,151 shares, along with stock option grant.

Director Jay Pepose reports receiving restricted stock units and stock options from Ocuphire Pharma.

Director James S. J. Manuso reports acquisition and disposal of Ocuphire Pharma, Inc. stock and stock options.

Director Cam Gallagher received stock and option awards from Ocuphire Pharma, as reported in a Form 4 filing with the SEC.

Director Susan Benton reports the acquisition of restricted stock units and stock options in Ocuphire Pharma.

Director Sean Ainsworth receives stock options and restricted stock units in Ocuphire Pharma, Inc.

Ashwath Jayagopal, Chief Scientific & Development Officer of Ocuphire Pharma, recently acquired 3,500 shares of common stock at a price of $1.765 per share.

Ocuphire Pharma's CEO, George Magrath, purchased 5,000 shares of common stock at an average price of $1.7545 on May 17, 2024.

Director Jay Pepose of Ocuphire Pharma, Inc. reports acquisition of restricted stock units and stock options.

Joseph K. Schachle, Chief Operating Officer of Ocuphire Pharma, Inc., recently purchased 2,000 shares of the company's common stock at a price of $2.05 per share.

Nirav S. Jhaveri, CFO of Ocuphire Pharma, Inc., reports the purchase and disposal of company stock on March 21, 2024.

Ocuphire Pharma's CEO, George Magrath, recently acquired 25,000 shares of common stock at an average price of $1.962 per share, increasing his direct holdings in the company.